{
  "docId": "019de517-44b3-71b5-8a8d-243b41bb1797",
  "docSlug": "c77cf9536b998c2f906519be4212f807",
  "documentTitle": "GH Research | Investor Presentation Deck | 30 slides",
  "authorId": "gh-research",
  "authorName": "GH Research",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 30,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "other",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 5,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de517-44b3-71b5-8a8d-243b41bb1797/18",
  "deckHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797",
  "deckJsonHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797.json",
  "deckAnchorHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.635,
        "w": 0.514,
        "x": 0.068,
        "y": 0.198
      },
      "kind": "chart",
      "text": "MADRS Remission / Response / Improvement Rate Day 7\n100%\n90%\n80%\n70%\n60%\n50%\n40%\n30%\n20%\n10%\n0%\n87.5%\n87.5%\n100%\nIndividualized Dosing Regimen\nMADRS remission\nMADRS response\nMADRS any improvement",
      "attrs": {
        "chart_type": "bar",
        "data_points": [
          {
            "x": "Individualized Dosing Regimen",
            "y": 0.875,
            "series": "MADRS remission"
          },
          {
            "x": "Individualized Dosing Regimen",
            "y": 0.875,
            "series": "MADRS response"
          },
          {
            "x": "Individualized Dosing Regimen",
            "y": 1,
            "series": "MADRS any improvement"
          }
        ],
        "x_axis_label": "Individualized Dosing Regimen",
        "y_axis_label": "Percentage",
        "series_labels": [
          "MADRS remission",
          "MADRS response",
          "MADRS any improvement"
        ]
      },
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12384c05-a3ca-4f09-ad2c-d18d92bbaa3e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.236,
        "w": 0.359,
        "x": 0.604,
        "y": 0.324
      },
      "kind": "list",
      "text": "Primary endpoint met:\n7 of 8 patients (87.5%) had a\nMADRS remission at day 7, p<0.0001\n7 of 8 patients had a PE and 6 of those had a\nMADRS remission at day 7",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c7eedb4-a22a-418b-8e3a-55debe2ff375",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.551,
        "x": 0.0703,
        "y": 0.883
      },
      "kind": "source-note",
      "text": "PE, Peak Experience; MADRS, Montgomery-Åsberg Depression Rating Scale\nMADRS remission = MADRS of ≤10; MADRS response = Reduction of ≥50% from baseline in MADRS; MADRS any improvement = any reduction from baseline in MADRS.",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "37583d1f-af98-4cbd-beb3-d778312664f6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.068,
        "w": 0.5094,
        "x": 0.0703,
        "y": 0.096
      },
      "kind": "title",
      "text": "Phase 2 (IDR) – Efficacy (MADRS)",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e518f02-d745-4f8f-9eb7-302b42ade91f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 30,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e59b812c-5781-40d1-880d-5eb666da502e",
      "evidence": "The document emphasizes the limitations of current treatments and the potential of GH001",
      "position": 0,
      "objective": "Highlight the need for more effective depression treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 30,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "a0a779b4-6b2d-4f03-ae8f-5683cc3e54fa",
      "evidence": "The document presents a clear 'why' for GH001, highlighting its potential to provide ultra-rapid, durable remissions",
      "position": 1,
      "objective": "Explain why GH001 is a necessary solution",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}